(function(){var loadHandler=window['sl_{A5D09008-4BBD-4F08-AA74-C540D1193457}'];loadHandler&&loadHandler(19, '<div id="spr0_3cce3b1"><div id="spr1_3cce3b1" class="kern slide"><img id="img1_3cce3b1" src="data/img3.png" width="1280px" height="720px" alt="" style="left:0px;top:0px;"/><div id="svg0_3cce3b1" style="top:128.672px;"><svg width="1280" height="7" viewBox="0 0 1280 7"><path fill="#800000" d="M0,0 h1280 v6.074 h-1280 Z"/></svg></div><div id="spr3_3cce3b1" style="left:1211.535px;top:695.766px;"><div style="width:0px;"><span id="txt0_3cce3b1" class="nokern" data-width="12.164063" style="left:46.767px;top:3.282px;">20</span></div></div></div><div id="spr2_3cce3b1" class="kern slide"><div id="spr4_3cce3b1" style="left:64px;top:62.634px;"><div style="width:0px;"><span id="txt1_3cce3b1" class="nokern" data-width="971.484375" style="left:9.6px;top:-4.755px;">Can all aspects of HTA be harmonized across EU?</span></div></div><div id="spr5_3cce3b1" style="left:64px;top:136.89px;"><div style="width:0px;"><span id="txt2_3cce3b1" data-width="1054.186768" style="left:9.6px;top:-6.634px;">The issue of transferability of Economic Evaluations</span></div></div><div id="spr6_3cce3b1" style="left:10.667px;top:669.651px;"><div style="width:0px;"><span id="txt3_3cce3b1" class="nokern" data-width="934.224304" style="left:9.6px;top:8.492px;">Kaló Z, Landa K, Doležal T, Vokó Z. Transferability of NICE recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries,</span></div><div style="width:0px;"><span id="txt4_3cce3b1" class="nokern" data-width="331.229492" style="left:9.6px;top:24.332px;">European Journal of Cancer Care, 2012. 21. 4. 442-449.</span></div></div><div id="spr7_3cce3b1" style="top:193.185px;"><img id="img0_3cce3b1" src="data/img21.png" width="1279.5" height="489" alt="" style="left:0.188px;top:-0.255px;"/></div></div></div>', '{"s":[]}');})();